Login
- Document type:
- Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Article
- Author(s):
- Graux, Carlos; Sonet, Anne; Maertens, Johan; Duyster, Justus; Greiner, Jochen; Chalandon, Yves; Martinelli, Giovanni; Hess, Dagmar; Heim, Dominik; Giles, Francis J; Kelly, Kevin R; Gianella-Borradori, Athos; Longerey, Blandine; Asatiani, Ekaterine; Rejeb, Narmyn; Ottmann, Oliver G
- Title:
- A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.
- Abstract:
- A phase I dose-escalation study of MSC1992371A, an oral aurora kinase inhibitor, was carried out in patients with hematologic malignancies. Patients received escalating doses either on days 1-3 and 8-10 (n=36) or on days 1-6 (n=39) of a 21-day cycle. The maximum tolerated doses were 37 and 28 mg/m(2)/day, respectively. Dose-limiting toxicities included severe neutropenia with infection and sepsis, mucositis/stomatitis, and diarrhea. Complete responses occurred in 3 patients. Four disease-specifi... »
- Journal title abbreviation:
- Leuk Res
- Year:
- 2013
- Journal volume:
- 37
- Journal issue:
- 9
- Pages contribution:
- 1100-6
- Language:
- eng
- Fulltext / DOI:
- doi:10.1016/j.leukres.2013.04.025
- Pubmed ID:
- http://view.ncbi.nlm.nih.gov/pubmed/23746966
- Print-ISSN:
- 0145-2126
- TUM Institution:
- III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX